Health Bulletin 23/September/2023

Here are the top health stories for the day:

NEET SS 2023 admit card out

The National Board of Examinations (NBE) has released the admit card for NEET SS Examinations to be held on 29th September 2023 and 30th September 2023.

The admit card is available live on the National Board of Examination in Medical Sciences website www.https:// natboard.edu.in. Admit cards are not issued to candidates found ineligible. It will not be sent to the candidates by Post/Email.

For more details, check out the link given below:

NEET SS 2023 Admit Card OUT

Where to send the essentiality certificate? NMC issues notice, reiterates deadline

Through a recent public notice, the Medical Assessment and Rating Board (MARB) of the National Medical Commission (NMC) has notified about the email address for submitting the Essentiality Certificate (in revised Form-2).

NMC has informed that the stakeholders who have applied through the online portal for the next academic year, can submit the document in the modified format through e-mail at ug.marb@nmc.org.in. For this purpose, NMC has set the deadline till October 13, 2023.

For more details, check out the link given below:

Where To Send The Essentiality Certificate? NMC Issues Notice, Reiterates Deadline

Nirma to buy 75 percent stake in Glenmark Life Sciences from Glenmark Pharma

Glenmark Pharmaceuticals Limited, a research-led, integrated, global pharmaceutical company has entered into a definitive agreement with Nirma Limited to divest 75% stake in its subsidiary, Glenmark Life Sciences Limited (GLS), at a price of INR 615/- per share for an aggregate consideration of INR 56,515 mn, subject to closing adjustments. Glenmark Pharma will own 7.84% in GLS after the divestment.

For more details, check out the link given below:

Glenmark Pharma To Divest 75 Percent Stake In Glenmark Life Sciences To Nirma For Rs 5651 Crore

Alkem Labs brands API business as Alkem Activa

Alkem Laboratories Ltd. has announced the branding of their active pharmaceutical ingredients (API) business as Alkem Activa.

"Alkem Activa signifies a pivotal move for Alkem Laboratories as the company is dedicated to producing a diverse range of high-quality APIs that cater to the evolving needs of the pharmaceutical industry. Moreover, Alkem Activa reflects Alkem’s focus on sustainability and ensures that it remains at the forefront of API innovation through responsible practices.

For more details, check out the link given below:

Alkem Labs Brands API Business As Alkem Activa

Anti-obesity drugs impact more than just weight loss

New anti-obesity drugs have the potential to transform public health while obliterating demand for products and services from the medical, food, and fitness industries. Think of them as total unaddressable markets (TUM). New anti-obesity drugs have the potential to transform public health while obliterating demand for products and services from the medical, food, and fitness industries.

Drugs developed by Novo Nordisk and Eli Lilly appear to be the first truly effective diet treatments. These drugs function by targeting brain receptors, diminishing appetite, and extending the sensation of fullness. In a clinical trial, patients who used Eli Lilly's soon-to-be-released weight-loss medication experienced an impressive weight loss of approximately 50 pounds (23 kg). The potential benefits for public health are substantial.

In August, Novo reported that Wegovy, its obesity drug, reduced the occurrence of severe cardiovascular events like strokes and heart attacks by 20% in overweight patients with a history of heart disease but no diabetes.